1 | options | 6,160 |
2 | panel-iii | 5 |
3 | nanoplatform | 4 |
4 | retention/completion | 3 |
5 | cyclohexanes | 2 |
6 | interventions/treatments | 2 |
7 | strongholds | 2 |
8 | 159·2 | 1 |
9 | 4.2±0.7 | 1 |
10 | 71.44±21.98 | 1 |
11 | 72.13±33.24 | 1 |
12 | abstentions | 1 |
13 | addressly | 1 |
14 | agents-the | 1 |
15 | aglycosylated | 1 |
16 | alone.however | 1 |
17 | approaches-neodymium-yttrium | 1 |
18 | arm. | 1 |
19 | arm.secondary | 1 |
20 | arsenals | 1 |
21 | benefi | 1 |
22 | center/halfway | 1 |
23 | comparisons.overall | 1 |
24 | completion.multi-micronutrient | 1 |
25 | contact-the | 1 |
26 | difference=-2.56 | 1 |
27 | difference=-3.32 | 1 |
28 | dropout/participation | 1 |
29 | duplicities | 1 |
30 | duration-dependant | 1 |
31 | effect=3.01 | 1 |
32 | effectiveness-i.e. | 1 |
33 | entry/attendance | 1 |
34 | failure-overall | 1 |
35 | failures.however | 1 |
36 | goals… | 1 |
37 | group.it | 1 |
38 | groups-including | 1 |
39 | groups-paroxetine-only | 1 |
40 | groups-saline | 1 |
41 | groups.insulin | 1 |
42 | grup | 1 |
43 | guideline-papers | 1 |
44 | in-hand | 1 |
45 | intervention/s | 1 |
46 | macrosolute | 1 |
47 | modalities-the | 1 |
48 | of.56 | 1 |
49 | ofamenorrhea | 1 |
50 | ofidiopathic | 1 |
51 | ofphotoinduced | 1 |
52 | ofrftvr | 1 |
53 | options.this | 1 |
54 | orders-glu-asp-lis | 1 |
55 | outcome/improvement | 1 |
56 | panel-3 | 1 |
57 | paradigms-recovery | 1 |
58 | period.bronchial | 1 |
59 | periods-if | 1 |
60 | plans.there | 1 |
61 | procedures-hemostasis | 1 |
62 | safety.this | 1 |
63 | satisfaction-visual | 1 |
64 | schedule.the | 1 |
65 | sequencies | 1 |
66 | spophyllin | 1 |
67 | strategems | 1 |
68 | strategies-beta-blockers | 1 |
69 | strategy.an | 1 |
70 | system-paediatric | 1 |
71 | trial-normative | 1 |
1 | 159·2 | 1 |
2 | 4.2±0.7 | 1 |
3 | 71.44±21.98 | 1 |
4 | 72.13±33.24 | 1 |
5 | abstentions | 1 |
6 | addressly | 1 |
7 | agents-the | 1 |
8 | aglycosylated | 1 |
9 | alone.however | 1 |
10 | approaches-neodymium-yttrium | 1 |
11 | arm. | 1 |
12 | arm.secondary | 1 |
13 | arsenals | 1 |
14 | benefi | 1 |
15 | center/halfway | 1 |
16 | comparisons.overall | 1 |
17 | completion.multi-micronutrient | 1 |
18 | contact-the | 1 |
19 | cyclohexanes | 2 |
20 | difference=-2.56 | 1 |
21 | difference=-3.32 | 1 |
22 | dropout/participation | 1 |
23 | duplicities | 1 |
24 | duration-dependant | 1 |
25 | effect=3.01 | 1 |
26 | effectiveness-i.e. | 1 |
27 | entry/attendance | 1 |
28 | failure-overall | 1 |
29 | failures.however | 1 |
30 | goals… | 1 |
31 | group.it | 1 |
32 | groups-including | 1 |
33 | groups-paroxetine-only | 1 |
34 | groups-saline | 1 |
35 | groups.insulin | 1 |
36 | grup | 1 |
37 | guideline-papers | 1 |
38 | in-hand | 1 |
39 | intervention/s | 1 |
40 | interventions/treatments | 2 |
41 | macrosolute | 1 |
42 | modalities-the | 1 |
43 | nanoplatform | 4 |
44 | of.56 | 1 |
45 | ofamenorrhea | 1 |
46 | ofidiopathic | 1 |
47 | ofphotoinduced | 1 |
48 | ofrftvr | 1 |
49 | options | 6,160 |
50 | options.this | 1 |
51 | orders-glu-asp-lis | 1 |
52 | outcome/improvement | 1 |
53 | panel-3 | 1 |
54 | panel-iii | 5 |
55 | paradigms-recovery | 1 |
56 | period.bronchial | 1 |
57 | periods-if | 1 |
58 | plans.there | 1 |
59 | procedures-hemostasis | 1 |
60 | retention/completion | 3 |
61 | safety.this | 1 |
62 | satisfaction-visual | 1 |
63 | schedule.the | 1 |
64 | sequencies | 1 |
65 | spophyllin | 1 |
66 | strategems | 1 |
67 | strategies-beta-blockers | 1 |
68 | strategy.an | 1 |
69 | strongholds | 2 |
70 | system-paediatric | 1 |
71 | trial-normative | 1 |
1 | effectiveness-i.e. | 1 |
2 | arm. | 1 |
3 | effect=3.01 | 1 |
4 | difference=-3.32 | 1 |
5 | 159·2 | 1 |
6 | panel-3 | 1 |
7 | 72.13±33.24 | 1 |
8 | difference=-2.56 | 1 |
9 | of.56 | 1 |
10 | 4.2±0.7 | 1 |
11 | 71.44±21.98 | 1 |
12 | ofamenorrhea | 1 |
13 | ofidiopathic | 1 |
14 | system-paediatric | 1 |
15 | ofphotoinduced | 1 |
16 | aglycosylated | 1 |
17 | in-hand | 1 |
18 | entry/attendance | 1 |
19 | modalities-the | 1 |
20 | agents-the | 1 |
21 | contact-the | 1 |
22 | schedule.the | 1 |
23 | groups-saline | 1 |
24 | plans.there | 1 |
25 | macrosolute | 1 |
26 | trial-normative | 1 |
27 | periods-if | 1 |
28 | groups-including | 1 |
29 | benefi | 1 |
30 | panel-iii | 5 |
31 | period.bronchial | 1 |
32 | satisfaction-visual | 1 |
33 | failure-overall | 1 |
34 | comparisons.overall | 1 |
35 | nanoplatform | 4 |
36 | approaches-neodymium-yttrium | 1 |
37 | strategy.an | 1 |
38 | spophyllin | 1 |
39 | groups.insulin | 1 |
40 | dropout/participation | 1 |
41 | retention/completion | 3 |
42 | grup | 1 |
43 | alone.however | 1 |
44 | failures.however | 1 |
45 | ofrftvr | 1 |
46 | intervention/s | 1 |
47 | strongholds | 2 |
48 | sequencies | 1 |
49 | duplicities | 1 |
50 | cyclohexanes | 2 |
51 | options.this | 1 |
52 | safety.this | 1 |
53 | orders-glu-asp-lis | 1 |
54 | procedures-hemostasis | 1 |
55 | arsenals | 1 |
56 | strategems | 1 |
57 | abstentions | 1 |
58 | options | 6,160 |
59 | strategies-beta-blockers | 1 |
60 | guideline-papers | 1 |
61 | interventions/treatments | 2 |
62 | group.it | 1 |
63 | duration-dependant | 1 |
64 | completion.multi-micronutrient | 1 |
65 | outcome/improvement | 1 |
66 | center/halfway | 1 |
67 | groups-paroxetine-only | 1 |
68 | addressly | 1 |
69 | arm.secondary | 1 |
70 | paradigms-recovery | 1 |
71 | goals… | 1 |